Thus, in mice with melanoma, while IgG2a administration prevents the skeletal muscle mitochondria adaptation to exercise, the anti-PD-1 therapy is able to preserve the typical increase in mitochondrial protein content occurring with training. Here, PDCD1 is linked to melanoma.